# Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

> **NCT01297400** · PHASE2 · RECRUITING · sponsor: **Skingenix, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Burns

## Interventions

- **DRUG:** Investigational Drug, MW-III
- **DRUG:** Silvadene® Cream 1% [Silver Sulfadiazine]

## Key facts

- **NCT ID:** NCT01297400
- **Lead sponsor:** Skingenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297400, "Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01297400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*